Pfizer CEO: Company refused taxpayer money for COVID-19 vaccine development to 'liberate our scientists'


Pfizer chose not to take U.S. taxpayer money to help fund its coronavirus vaccine development, a move that CBS News' Margaret Brennan pointed out on Sunday is a bit of a financial risk for the pharmaceutical giant.
CEO Albert Bourla admitted that it will indeed "be painful" if the vaccine fails, but "at the end of the day it's only money" and the lack of taxpayer funds won't "break our company." It was more important for Bourla that his scientists were able to work without any strings attached, he said. "I wanted to liberate our scientists from any bureaucracy," he continued. "When you get money from someone, that always comes with strings. They want to see how we are growing to progress, what types of moves you are going to do. They want reports. I didn't want to have any of that."
Bourla said he gave Pfizer's team an "open checkbook" so they only have to worry about "scientific challenges." Plus, he added, he wanted to keep Pfizer out of politics, a tall task for a pharma company on any day, but especially during this pandemic.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
As for the vaccine itself, Bourla said Pfizer is preparing for a situation in which they'll know if the candidate works by the end of October, adding that "I cannot say what" the Food and Drug Administration "will do" after that, but "I think it's a likely scenario" the product could receive federal approval before the end of the year. Read more at The Hill.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
By Peter Weber, The Week US
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
By Peter Weber, The Week US
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
By Peter Weber, The Week US
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US